Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04711746
Recruiting Not applicable

Is Clonal Hematopoiesis of Indeterminate Potential Associated With Unprovoked Pulmonary Embolism?

NCT04711746 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Not applicable
Started
2021-02-01
Last updated
2025-05-29

Condition(s) studied

Pulmonary EmbolismHematopoiesis

Investigational drug(s) / intervention(s)

blood sample →

blood sample: Blood sample withdrawal in order to perform DNA sequencing

Study summary

The clonal hematopoiesis of indetermined prognosis (CHIP) has been described as risk factor for juvenile atherosclerosis. Moreover, some of CHIP genes are responsible of myeloproliferative disorders. Venous thrombosis are frequent in these disorders. The purpose of this project is to determine if CHIP is frequent in unprovoked pulmonary embolism and could be part of the pathophysiology.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * For cases : Previous proximal unprovoked pulmonary embolism, negative thrombophilia screening. * For control : Previous proximal provoked pulmonary embolism, negative thrombophilia screening. Exclusion Criteria: * Age superior to 65 years old, * Active cancer

Primary outcome measure(s)

  • Variation of CHIP markers between patients groups — up to 2 years
    Variation of CHIP markers (clonal hematopoiesis of indetermined prognosis ) between patients groups. CHIP concept have been defined as a mutation of preleukemic genes at an allelic variation inferior to 2% associated with normal complete blood count.

Trial sites (1)

FacilityCityRegionStatus
CHU Amiens Amiens France Recruiting

More Centre Hospitalier Universitaire, Amiens trials in France

Augmented Bladder Tumor Detection Using Real Time Based Artificial Intelligence Recruiting
Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection Recruiting
Validation, in a Pediatric Population, of a French Translation of the MEPS/MEPI Score Recruiting
Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease Recruiting
Interest of Prior Relaxation on the Recordings of the SomatoSensory Evoked Potentials Recruiting

Other trials for the same condition

Duration of Therapeutic Anticoagulation in Patients With Pulmonary Embolism Recruiting
Impact on Quality of Life With Pulmonary RehAbilitation After Pulmonary eMBOlism: RAMBO Study Recruiting
Evaluation of the PERC Score and the YEARS Algorithm in the Diagnosis of Pulmonary Embolism in the Emergency Department Recruiting
RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing Recruiting
Exclusion of Venous Thrombo-Embolism With a New Clinical Decision Support Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04711746 on ClinicalTrials.gov ↗ ← All trials in France